On November 30, 2023, the pharmaceutical awards Russian Pharma Awards® ceremony was held in Moscow.

This year the award, also known as the Oscars for Medicine, was granted for the 12th time. In the award, more than 70 drugs were nominated in 25 categories, and more than 430,000 practitioners were invited to vote.

Etorelex® produced by Pharmasyntez JSC was the "Selective COX-2 inhibitor for pain syndrome" nominee. As a result of voting, the drug received the highest marks from the physicians and ranked first! 

Etorelex® (INN Etoricoxib) is a non-steroid anti-inflammatory drug, selective cyclooxygenase-2 inhibitor, intended for the symptomatic therapy of osteoarthritis, rheumatoid arthritis, ankylosing spondylitis, pain and inflammation associated with acute gouty arthritis. The drug is also prescribed for short-term therapy of pain after dental surgeries.

The recognition from physicians is the best award and assessment for the Pharmasyntez Group of Companies, which shows that the company's products are really trusted by the most important and demanding consumers.